Back to Search
Start Over
Multi-target-directed ligands to combat neurodegenerative diseases
- Source :
- Journal of medicinal chemistry. 51(3)
- Publication Year :
- 2008
-
Abstract
- Our understanding of the pathogenesis of diseases has advanced enormously in recent decades. As a consequence, drug discovery has gradually shifted from an entirely humanphenotype-based endeavor to today’s reductionist approach centered on single molecular targets. The focus has shifted from the early animal models to isolated proteins via cellular models. This change has led to a decrease in complexity but also to a decrease in relevance to the human condition. In this context, drug research has become (and still is) aimed mainly at the discovery of small molecules able to modulate the biological function of a single protein target thought to be fully responsible for a certain disease. Much effort has been devoted to achieving selectivity for that given target, and indeed, nowadays, many ligands endowed with outstanding in vitro selectivity are available. This one-molecule, one-target paradigm has led to the discovery of many successful drugs, and it will probably remain a milestone for years to come. However, it should be noted that a highly selective ligand for a given target does not always result in a clinically efficacious drug. This may be because (a) the ligand does not recognize the target in vivo, (b) the ligand does not reach the site of action, or (c) the interaction with the respective target does not have enough impact on the diseased system to restore it effectively. Reasons for the latter might lie in both the multifactorial nature of many diseases and the fact that cells can often find ways to compensate for a protein whose activity is affected by a drug, by taking advantage of the redundancy of the system, i.e., of the existence of parallel pathways. Medicinal chemists are often faced with these frustrating aspects of drug research. Drawbacks a and b can be addressed through the well-established rational ligand modification approaches. But issue c is more problematic and needs to be carefully discussed. This is one of the aims of the present article.
- Subjects :
- medicine.medical_specialty
Multiple Sclerosis
Context (language use)
Plaque, Amyloid
NERVOUS SYSTEM
Ligands
Antioxidants
Multi target
Alzheimer Disease
Internal medicine
Drug Discovery
medicine
REVIEW
Humans
NEURODEGENERATIVE DESEASES
Chelating Agents
Neurotransmitter Agents
Amyloid beta-Peptides
Binding Sites
Chemistry
Drug discovery
Neurodegenerative Diseases
Neurofibrillary Tangles
Parkinson Disease
Highly selective
Calcium Channel Blockers
Small molecule
NEUROPROTECTIVE AGENTS
Endocrinology
Huntington Disease
Molecular targets
Acetylcholinesterase
Molecular Medicine
DRUG DESIGN
Cholinesterase Inhibitors
Protein target
Neuroscience
Site of action
Subjects
Details
- ISSN :
- 00222623
- Volume :
- 51
- Issue :
- 3
- Database :
- OpenAIRE
- Journal :
- Journal of medicinal chemistry
- Accession number :
- edsair.doi.dedup.....9a6658c4ffe25cdb339ce1edd433ef50